Skip to content
2000
Volume 16, Issue 19
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Preclinical studies show that antagonism of the GABAB receptor may represent an effective neuropharmacological approach to treat alcohol dependence. Consistent with preclinical evidence, the majority of the human studies have demonstrated that the prototype GABAB receptor antagonist baclofen may represent an effective mediation to treat alcohol-dependent individuals. Specifically, baclofen has shown to reduce alcohol withdrawal symptoms, as well as to reduce alcohol craving and intake, and to promote alcohol abstinence. Notably, baclofen has shown a safe profile when administered to alcoholics, including those with liver cirrhosis. In summary, baclofen represents a safe and effective medication to treat alcohol dependence, thus holding promise as a new pharmacotherapy. However, large studies are needed to confirm the present findings.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161210791516440
2010-06-01
2025-06-15
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161210791516440
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test